The gut-based cancer and inflammatory disease drug developer has raised almost $170m from investors including Celgene, GV and Mayo Clinic.
US-based gut-body therapy developer Evelo Biosciences has filed for a $100m initial public offering that will enable pharmaceutical firm Celgene, internet technology group Alphabet and medical researcher Mayo Clinic to exit.
Evelo is working on monoclonal microbials cloned from a single naturally-occurring microbe which are intended to leverage the role of the gastrointestinal tract, or gut, in controlling immune and biological activity in the human body.
The proceeds will fund proof-of-concept clinical trials for Evelo’s oncology and inflammatory diseases…
